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Abstract
Purpose: The observation that human meningioma cells strongly express somatostatin receptor
(SSTR 2) was the rationale to analyze retrospectively in how far DOTATOC PET/CT is helpful to
improve target volume delineation for intensity modulated radiotherapy (IMRT).
Patients and Methods: In 26 consecutive patients with preferentially skull base meningioma,
diagnostic magnetic resonance imaging (MRI) and planning-computed tomography (CT) was
complemented with data from [68Ga]-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT.
Image fusion of PET/CT, diagnostic computed tomography, MRI and radiotherapy planning CT as
well as target volume delineation was performed with OTP-Masterplan®. Initial gross tumor
volume (GTV) definition was based on MRI data only and was secondarily complemented with
DOTATOC-PET information. Irradiation was performed as EUD based IMRT, using the Hyperion
Software package.
Results: The integration of the DOTATOC data led to additional information concerning tumor
extension in 17 of 26 patients (65%). There were major changes of the clinical target volume (CTV)
which modify the PTV in 14 patients, minor changes were realized in 3 patients. Overall the GTV-
MRI/CT was larger than the GTV-PET in 10 patients (38%), smaller in 13 patients (50%) and almost
the same in 3 patients (12%). Most of the adaptations were performed in close vicinity to bony skull
base structures or after complex surgery. Median GTV based on MRI was 18.1 cc, based on PET
25.3 cc and subsequently the CTV was 37.4 cc. Radiation planning and treatment of the
DOTATOC-adapted volumes was feasible.
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Conclusion: DOTATOC-PET/CT information may strongly complement patho-anatomical data
from MRI and CT in cases with complex meningioma and is thus helpful for improved target volume
delineation especially for skull base manifestations and recurrent disease after surgery.
Introduction
Meningiomas represent about 20% of all intracranial
brain tumors and are therefore the most frequent nonglial
brain tumors in adults with a clear predomination in
women (f/m 2:1) [1]. More than 90% are histological
benign of mesodermal origin arising from the arachnoid
meninges of the brain and are slow-growing with a low
proliferation index. Atypical or malignant histology is rare
and often requires multimodal treatment caused by
increased local relapse.
Particularly meningiomas of the skull base are difficult to
treat due to their close relation to critical structures like
brainstem, major vessels and cranial nerves.
Although surgical resection of meningioma is the pre-
ferred treatment approach, ionizing radiation is a highly
effective treatment modality. After complete surgical
resection long-term recurrence-free survival can be
achieved up to 93 and 80% after 5 and 10 years, respec-
tively. Without total removal the recurrence-free survival
is inferior, up to 65 and 45% or worse after 5 and 10 years,
respectively [1-4]. Adjuvant radiotherapy (RT) can
improve local tumor control and overall survival after
incomplete surgical resection [5-8]. Similar to resection,
radiotherapy alone offers 5-year local control above 90%
[9,10]. However, the surrounding tissue and the benign
histology mandate extreme precision during treatment
planning in order to minimize the risk of side effects.
Therefore stereotactic fractionated treatment protocols
comprise the standard radiotherapy approach. Similar to
numerous different malignancies treated with intensity-
modulated RT [11-13], recently several IMRT based proto-
cols for meningiomas have been issued offering even
higher target volume conformity and improved normal
tissue protection [14-19]. With increasing conformity the
need for accurate target volume delineation is of outmost
importance. Of special importance is the fact that target
volume definition after single or repeated surgical inter-
vention is frequently hampered by artifacts. In general the
use of highly conformal treatment techniques mandates
improved pretherapeutic imaging. In this regard, positron
emission tomography (PET) based techniques as well as
other functional imaging modalities including SPECT-CT
or also MRI enter the routine in radiation oncology [20-
26].
Up to now treatment planning was mainly based on com-
binations of contrast enhanced CT and MRI. Especially
after repetitive surgery and in case of an infiltrative growth
pattern these imaging modalities have their limitations.
Meningioma cells strongly express somatostatin receptor
subtype 2 (SSTR 2) which offers an additional positron
emission tomography (PET) based imaging for tumor
delineation with the somatostatin-receptor ligand [68Ga]-
DOTA-D Phe1-Tyr3-Octreotide (DOTATOC) [27]. DOTA-
TOC-PET/CT shows a high meningioma to background
ratio which can be used to improve target volume defini-
tion prior to IMRT [28,29].
To document the value of [68Ga]-DOTATOC-PET/CT for
treatment planning of complex meningiomas preferen-
tially of the skull base we retrospectively analyzed a series
of patients in whom CT/MRI based treatment planning
was complemented by [68Ga]-DOTATOC-PET/CT.
Patients and Methods
Patients
26 consecutive patients with preferentially skull base
meningiomas received diagnostic MRI, RT planning CT
and additional [68Ga]-DOTATOC-PET/CT prior to frac-
tionated stereotactic IMRT between 2007 and 2008 in our
institution. 20 meningiomas were located at the skull
base, one was an optic nerve sheath meningioma. Median
age at treatment was 59.5 years (range 28-82 years). The
male/female ratio was 3/23, median Karnofsky perform-
ance score was 90% (range 70-100%). 19 of the 26
patients underwent surgical treatment or extended biopsy,
13 once, five twice and one woman for three times before
start of RT. The pathological examination revealed a
World Health Organization (WHO) grade I meningioma
in 14 and a WHO grade II tumor in four patients. One
young patient with a WHO grade II meningioma received
a prior prophylactic radiation of the brain with a cumula-
tive dose of 18 Gy due to the therapy regime of a hemato-
logical disorder 26 years before. Seven patients received
IMRT as primary treatment without proven histology
because biopsy was concluded to be infeasible. In these
cases diagnosis of meningioma was based on CT and MRI
offering typical radiologic characteristics of a benign men-
ingioma. Characteristics of the patients are listed in Table
1.
[68Ga]-DOTATOC-PET/CT
Imaging was performed using a dedicated PET/CT scanner
(Biograph 16 HiRez; Siemens Medical Solutions, Erlan-
gen, Germany).Radiation Oncology 2009, 4:56 http://www.ro-journal.com/content/4/1/56
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Forty minutes after intravenous injection of 150 MBq
[68Ga]-DOTATOC the combined examination com-
menced with a topogram to define the PET/CT examina-
tion range (2 fields of view (FOV)). Non-contrast CT scans
were performed firstly for attenuation correction of PET
data and for anatomic correlation. Subsequently the PET
scan was done acquiring static emission data for 4 min-
utes per FOV.
PET images were reconstructed by using an iterative algo-
rithm (ordered-subset expectation maximization: 4 itera-
tions, 8 subsets). Non-enhanced CT data were
reconstructed with a slice thickness of 5 mm (axial) and
an increment of 5 mm.
The reconstructed PET, CT and fused images were dis-
played on the manufacturer's workstation (e-soft, Sie-
mens Medical Solutions) in axial, coronal and sagittal
planes with a resolution of 128 × 128 pixels for the PET
and 512 × 512 pixels for the CT images.
The fused PET/CT images were evaluated by two experi-
enced nuclear medicine experts and two experienced radi-
ologists in consensus. For all detected meningiomas the
standardized uptake value (SUV) was calculated using the
region of interest (ROI, 50% isocontour) method and was
corrected for weight.
Treatment planning and target volume definition
IMRT treatment planning was primarily based on diag-
nostic MRI data and was secondarily complemented by
the information from [68Ga]-DOTATOC-PET. Addition-
ally all patients routinely had a neuroophthalmological
and endocrinological examination and an audiometry. RT
planning was performed on a 3D-data set generated from
3 mm CT scans in treatment position. For immobilization
of the head an individual thermoplastic head mask fixa-
tion was used. Image fusion of diagnostic MRI, RT plan-
ning CT and PET/CT as well as target volume delineation
was done with OTP-Masterplan®  package (Theranostic
GmbH, Solingen, D). The CT planning images in mask
fixation were fused with the CT images derived from PET/
CT (CT to CT, additionally CT to diagnostic MRI) using
the automatic matching algorithm stored in the OTP-Mas-
terplan® system. As being initially linked to the combined
PET/CT images the raw PET data did not require a separate
image fusion.
For gross tumor volume (GTV) delineation the initial
macroscopic tumor volume definition was based on MRI
findings and RT planning CT information only (GTV-
MRI/CT). Subsequently the PET positive tumor lesions
were defined by the same therapist (GTV-PET). The GTV-
MRI/CT as well as the GTV-PET was counterchecked by an
advanced neuroradiologist or rather nuclear medicine
physician. MRI data were complemented by DOTATOC-
PET findings and additional clinical information (particu-
larly including potential areas of microscopic tumor
growth) with a resulting CTV. Finally the CTV was
expanded with an overall safety margin of 4 mm to the
PTV.
Table 1: Patients characteristics
Patients treated with IMRT n = 26
Patients (female/male) 23;3
Karnofsky Performance Scale (median/range) [%] 95 (70-100)
Age (median/range) [years] 60 (28-82)
Tumor site
Olfactorius nerve 5










resection for 1/2/3 times 13;5;1
Histology/WHO grading
WHO I 14
WHO II (atypical meningioma) 4
Tissue lost 1
Unknown (diagnosis based on MRI, CT) 7
Postoperative period until initiation of radiation (median/range) [months] 56.1 (3-249)Radiation Oncology 2009, 4:56 http://www.ro-journal.com/content/4/1/56
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For IMRT treatment planning organs at risk (brainstem,
optical nerves, chiasm, lens, internal ear and hippocam-
pus) were outlined. Irradiation was performed as EUD
(equivalent uniform dose)-based IMRT, using the Hyper-
ion® software package. Three-dimensional dose distribu-
tions were calculated and optimized via Monte Carlo dose
calculation using a multileaf collimator (leaf width: 4 mm
at isocenter). The purpose of treatment planning was to
cover the 95% isoline by the PTV. The dose prescription
was 54 Gy in total with a daily fraction dose of 1.8 Gy, 5
times a week. Patient positioning was verified by cone
beam CT imaging every day in the first week of irradiation
and afterwards twice a week.
Quantitative analysis of tumor volumes
For quantification of target volume changes based on the
PET findings we evaluated both the tumor volumes (GTV-
MRI/CT and GTV-PET) and intersection areas between the
GTV-MRI/CT and GTV-PET (Intersection-GTV-MRI/CT/
PET). For both modalities we computed the increase in
[cc] with respect to the intersection area (Increase-MRI/CT
vs. Intersection, respectively Increase-PET vs. Intersec-
tion). These areas are those, which are visible in one target
volume only. Finally the ratios between the increased vol-
umes with respect to the GTV-MRI/CT were assessed. In
order to report these volume values for the whole patient
collective pure descriptive statistics (mean, standard devi-
ation, median, maximum, minimum) were used.
Results
IMRT
A median treatment dose of 53 Gy (range 51.2-57 Gy)
could be achieved. IMRT was submitted with a 6/15 MV
linear accelerator (Elekta Synergy SBM XVI) and was car-
ried out on average with 8 beams (range 6-10) and 41 seg-
ments (range 17-70).
Target volume definition by MRI/CT
The GTV-MRI/CT included the macroscopic tumor visible
in the planning CT and contrast-enhanced T1-weighted
MRI. All meningiomas could be delineated on MRI and
CT. For the GTV-MRI/CT no safety margin was defined.
Median GTV-MRI/CT was 18.1 cc (mean: 27.5; range 1.2-
79.5 cc).
Target volume definition by [68Ga]-DOTATOC-PET
All 26 patients displayed a pronounced SSTR 2 tracer
retention within the meningioma. In addition to a strong
signal in three patients there were distant small spots
without a morphologic correlate in the cranial MRI, which
were not included in the GTV-PET.
There were several DOTATOC-PET positive lesions
beyond the cranium without any further suspicious tumor
detection in an additional CT or MRI examination.
Target volume definition based on [68Ga]-DOTATOC-PET
(GTV-PET) included the tumor volume with an intense
tracer uptake, all 26 meningiomas showed a high tumor-
to-background contrast. For the target volume definition
the windowing of the DOTATOC-PET was determined by
the optimal matching between the PET-positive areas and
the viewable tumor margins determined by CT/MRI. The
physiological signal of the bony skull and the air-filled
nasal cavity was masked out via windowing; neither a SUV
cut-off nor a safety margin was defined. In general, the dif-
ferentiation between the pituitary gland and adjacent
located tumor manifestations is mostly sophisticated
caused by the SSTR 2 expression of the gland itself. In
cases with PET positive tumor manifestations nearby the
pituitary gland, they were included completely if it was
not possible to distinguish gland from tumor manifesta-
tion. The median GTV-PET was 25.3 cc (mean: 33.5 cc;
range 0.6-106.1 cc).
Correlation of GTV-PET and GTV-MRI/CT - Multimodal 
target volume definition
In 17 of 26 patients DOTATOC-PET data led to additional
information concerning the tumor extension (examples
Figures 1, 2). Overall the GTV-MRI/CT was larger than the
GTV-PET in 10 patients, smaller in 13 patients and almost
the same in three patients (< = 0.7 cc deviation). Among
the 13 patients with a larger GTV-PET than GTV-MRI/CT
there were three patients with an inclusion of the pituitary
gland region caused by difficult discrimination gland
from tumor manifestation.
In 14 cases there were major changes of the clinical target
volume (CTV) based on PET findings (10 enlargements,
two reductions and in two cases areas of target volume
enlargement as well as reduction). Minor changes (only
changes at the borders of the target volume without affec-
tion of a new anatomical area) were seen in three patients
(three enlargements). Three cases showed a pronounced
enlargement of the CTV in the postoperative situation
based on enclosure of the PET positive resection hole.
Exemplarily, in one patient the conventional MRI imaging
showed no residual tumor growth after resection of an
olfactory's meningioma, whereas the additional PET data
revealed active tumor mass in the nasal cavity and in the
ethmoidal sinus. Therefore a clear enlargement of the CTV
(GTV-MRI/CT 13.6 cc; GTV-PET 18.2 cc; CTV 19.6 cc)
resulted. In one case there was a remarkable enlargement
of the CTV caused by a PET positive osseous lesion which
could not clearly be seen on MRI and CT imaging (GTV-
MRI/CT 69.3 cc; GTV-PET 94 cc; CTV 99 cc). In 9 of 26
patients DOTATOC-PET delivered no supplementary
information regarding tumor extension known from MRI
and CT. The median CTV as a summation of the GTV-
MRI/CT and the GTV-PET without a safety margin was
37.4 cc (mean 42.2 cc; range 1.3-143.2 cc). With theRadiation Oncology 2009, 4:56 http://www.ro-journal.com/content/4/1/56
Page 5 of 8
(page number not for citation purposes)
exception of three patients in the group of patients with
additional information from the DOTATOC-PET the CTV
was always larger than each single of the correlating GTV
(PET and MRI/CT). The PTV was created from the CTV
with an overall safety margin of 4 mm. Median PTV was
78.3 cc (mean: 92.3 cc; range 6.8-227.7 cc).
The median intersection volume of the GTV-MRI/CT and
the GTV-PET was 13.4 cc (mean 21.3 cc). The median vol-
ume increase based on the PET findings compared to the
intersection was 6.1 cc (mean 12.2 cc ± 13.3 cc), based on
the MRI and planning-CT data 5.7 cc (mean 6.2 cc ± 4.6
cc). Hence the increase is approximately the same for both
defined GTVs. The median ratio of the overall MRI-posi-
tive but PET-negative volume to the GTV-MRI/CT was
0.28 (mean 0.33 ± 0.21; range 0.02-0.75). The percentage
of enlargement over the GTV-MRI/CT based on DOTA-
TOC-PET was 0.31 (mean 1.03 ± 2.8; range 0-14.36, after
removing one patient with a PET-tracer uptake in the
resection hole without a visible tumor growth in the MRI,
the median ratio was 0.3 (mean 0.49 ± 0.68; range 0-3.1)
(Table 2). We conclude that about 30% of the GTV-MRI/
CT display no PET-tracer uptake and vice versa the volume
outside the GTV-MRI/CT with PET-tracer uptake not being
visible in the MRI/CT images has a volume approximately
of 30% of the GTV-MRI/CT.
Discussion
A wide range of publications has documented the value of
external beam radiation for the treatment of meningioma.
However clinical practice is more likely to show that only
those cases suffering from complex meningioma are
referred to radiotherapy. This included patients with
relapse after surgery, large tumors or complexly growing
tumor. Thus the treating physician is frequently faced with
the dilemma to spare as much of critical normal tissue
without missing gross tumor. The use of highly conformal
treatments including IMRT even increases the need for
optimal target volume delineation.
In the present study we evaluated the value of the [68Ga]-
DOTATOC-PET for treatment planning of intracranial
complexly shaped meningiomas. Up to now the follow up
time in our cohort is all too short to give some informa-
tion about local control after IMRT treatment. However,
our data show clearly that the use of [68Ga]-DOTATOC-
PET improved target volume delineation in a larger pro-
portion of our patients schedule for an IMRT based radia-
tion approach when compared to MRI based planning
alone. Particularly bony lesions or direct bone infiltration
by adjacent meningioma tissue were more likely to be
detected with PET. Basically we found a geographical miss
in 50% of the patients and - on the other hand - were able
Large skull base meningioma with orbital invasion and close relation to the sella turcica region, [68Ga]-DOTATOC-PET (top  left)/CT image fusion (top right) Figure 1
Large skull base meningioma with orbital invasion and close relation to the sella turcica region, [68Ga]-
DOTATOC-PET (top left)/CT image fusion (top right). Physiological tracer uptake of the pituitary gland. CTV/GTV 
contours (below left): red = GTV-PET; green = GTV-MRI/CT; yellow = CTV, CTV enlargement by GTV-PET. Dose distribu-
tion with enclosing 90% PTV isoline.Radiation Oncology 2009, 4:56 http://www.ro-journal.com/content/4/1/56
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to reduce the CTV in 38% of the patients. When compared
to other observations using [68Ga]-DOTATOC-PET, 11C-
Methionine [30,31] or 18F-Tyrosine [32], similar ranges
were reported in the term of PET scanning offering addi-
tional information. In this regard Milker-Zabel reported
relevant information in 19 out of 26 patients using
DOTATOC [33], Astner reported additional information
in 29 out of 32 patients [30] and Rutten reported changes
in 6 out of 13 lesions in 11 patients using 18F-Tyrosine
[32]. In our series in 17 out of 26 patients PET scanning
offered relevant complementary information.
When one analyzes the pattern of changes in more detail,
Milker-Zabel and Rutten reported larger proportions of
potential geographical misses avoided by PET scanning
(38% in both studies) [32,33]. This is in accordance with
our findings where the CTV was increased after inclusion
of the PET data (50%). In contrast, the study by Astner
reported a larger proportion of GTV/PTV reductions after
inclusion of 11C-Methionine-PET data when compared to
MRI scanning alone (75%) [30].
The reasons for these differences are not readily deducible
from the reported data. However, it may be speculated
that the inherent bias of patient selection and strategies
employed for MRI-GTV definition may be the underlying
reason. This assumption is supported by the fact that at
least comparable volumes were treated in all three studies
excluding the possibility that differences in tumor volume
are responsible for the differences in target volume
changes.
An important consideration in this context is the open
question if there is s SUV-threshold to define the GTV-
PET. In our study for the target volume definition the win-
dowing of the DOTATOC-PET was determined by the
matching between the PET-positive areas and the viewa-
ble tumor margins determined by CT/MRI. The physio-
logical signal of the bony skull and the air-filled nasal
cavity was masked out via windowing. Although a SUV-
threshold would be helpful for the GTV-DOTATOC-PET
delineation in meningiomas, up to know clear evidence
for a SUV cut-off is missing. Astner et al. [34] reported an
interesting phantom study in 11 patients with glomus
tumors and revealed that a value of 32% of the maximum
standardized uptake was an appropriate threshold for
tumor delineation. At the moment we do not have this
information for meningiomas in DOTATOC-PET imag-
ing. However, in regard to IMRT planning for meningi-
omas special biological characteristics of microscopic
tumor growth have to be taken into account especially for
CTV delineation. Hence in our opinion we have to be cau-
tious in reducing target volumes along an experimental
SUV-threshold alone.
From the data currently available it seems that either
[68Ga]-DOTATOC,  11C-Methionine or 18F-Tyrosine are
useful tracers for target volume definition in patients with
Recurrence of olfactory's meningioma (MRI left) Figure 2
Recurrence of olfactory's meningioma (MRI left). [68Ga]-DOTATOC-PET/CT image fusion with small distant lesion at 
the left dorsal orbital bone and physiological tracer uptake of the pituitary gland. Dose distribution (right) with inclusion of the 
small distant lesion and enclosing 90% PTV isoline.
Table 2: Treatment characteristics, target volumes
Median Maximum Minimum SD Mean
GTV-MRI/CT [cc] 18,1 79,5 1,2 23,5 27,5
GTV-PET [cc] 25,3 106,1 0,6 29,1 33,5
CTV [cc] 37,4 143,2 1,3 34,7 42,2
Intersection-GTV-MRI/CT/PET [cc] 13,4 78,2 0,3 21,5 21,3
Increase-MRI/CT vs Intersection [cc] 5,7 15,5 0,8 4,6 6,2
Increase-PET vs Intersection [cc] 6,1 48,8 0 13,2 12,2
Ratio Increase-MRI/CT to GTV-MRI/CT 0,28 0,75 0,02 0,21 0,33
Ratio Increase-PET to GTV-MRI/CT 0,31 14,36 0,00 2,80 1,03Radiation Oncology 2009, 4:56 http://www.ro-journal.com/content/4/1/56
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meningioma. Up to now there is no clear evidence availa-
ble supporting the superiority of any of the given tracers.
As stated above, meningiomas particularly show high lev-
els of somatostatin receptor expression (SSTR2) resulting
in a high tracer uptake. The usefulness of [68Ga]-DOTA-
TOC-PET for a distinction of meningioma from other
brain tumors has been well documented [35-37]. In sev-
eral disorders including metastasis or glioma Methionine
or Tyrosine may produce false positive results. However,
amino acid tracers like Methionine or Tyrosine are mark-
ers of amino acid transport and give some more informa-
tion in regard to metabolic activity of several tumor
tissues. At least Methionine-PET may help to judge the
aggressiveness of meningioma since the uptake has been
reported to correlate with the proliferative activity meas-
ured by the KI-67 index [38-40]. In our opinion for IMRT
planning it seems reasonable to use the tracer with the
highest inherent specificity which - by means of its mech-
anism of action - is [68Ga]-DOTATOC-PET.
A given disadvantage of DOTATOC is the fact that the
pituitary gland is generally highly positive and limits the
precision of target volume definition in this area.
Although PET/CT images have reached a considerable
level of spatial discrimination the current technology does
not allow for the visualization of microscopic tumor
growth along the dural membranes. Thus it will be still
necessary to add empirical margins to cover all areas.
Conclusion
[68Ga]-DOTATOC-PET/CT information strongly comple-
ments image data from MRI and CT in cases with complex
meningiomas of the skull base. In all meningioma
patients a tracer uptake of the [68Ga]-DOTATOC was seen.
Especially in patients with complex skull base meningi-
oma or recurrent disease [68Ga]-DOTATOC offers impor-
tant additional information. Therefore we would
recommend the use of the [68Ga]-DOTATOC for GTV def-
inition in all cases with complex meningioma.
Further evaluation with a larger number of patients seems
to be justified and long-term follow-up is needed to eval-
uate the clinical impact.
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